ANX Adventrx Pharmaceuticals Inc. featured news, full reports, and detailed charts
Adventrx Pharmaceuticals Inc. (ANX) Wrap Up:
ADVENTRX Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. Its lead product candidates include ANX-530, a novel emulsion formulation of chemotherapy drug vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, as well as to treat advanced or metastatic breast cancer; and ANX-514, a novel emulsion formulation of the chemotherapy drug docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers. The company was founded in 1995 is based in San Diego, California.Adventrx Pharmaceuticals, Inc. (ANX:AMEX)
Snapshot of Adventrx Pharmaceuticals, Inc. (ANX)
|
OPEN
$0.10
|
PREVIOUS CLOSE
$0.10
|
|
|
DAY HIGH
$0.10
|
DAY LOW
$0.09
|
|
|
52 WEEK HIGH
06/11/09 - $0.25
|
52 WEEK LOW
12/29/08 - $0.07
|
|
|
MARKET CAP
15.4M
|
AVERAGE VOLUME 3 mo
2.4M
|
|
|
DILUTED EPS TTM
$-0.18
|
SHARES OUTSTANDING
153.8M
|
|
|
ANX Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
ANX Top Compensated Officers
Executives, Board Directors
Key developments for Adventrx Pharmaceuticals, Inc. (ANX)
Adventrx Pharmaceuticals, Inc. expected to Report Fiscal Year 2009 Results on March 22, 2010. This event was calculated by Capital IQ (Created on November 13, 2009).
Adventrx Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the three months ended September 30, 2009, the company's net loss applicable to common stock was $2.7 million, or $0.02 per basic and diluted share, compared with a net loss applicable to common stock of $6.8 million, or $0.08 per basic and diluted share, for the comparable period in 2008. Included in the net loss applicable to common stock for the 2009 third quarter was a non-cash deemed dividend expense of $0.4 million incurred in connection with the Company's July and August 2009 equity financings. The company reported loss before income tax of $2.353 million and loss from operations of $2.350 million compared to loss before income tax of $6.777 million and loss from operations of $6.856 million for the same period of last year. For the nine months ended September 30, 2009, the company's net loss applicable to common stock was $9.7 million, or $0.10 per basic and diluted share, compared with a net loss applicable to common stock of $19.1 million, or $0.21 per basic and diluted share, for the comparable period in 2008. Included in the net loss applicable to common stock for the 2009 period was a non-cash deemed dividend expense of $1.6 million incurred in connection with the Company's June, July and August 2009 equity financings. Included in net loss and net loss applicable to common stock for the nine months ended September 30, 2009 were charges associated with the Company's reductions in force made in October 2008, and January and March 2009. The company reported loss before income tax of $8.105 million and loss from operations of $8.061 million on revenues of $300,000 compared to loss before income tax of $19.135 million and loss from operations of $19.779 million on revenues of $500,000 for the same period of last year.
Adventrx Pharmaceuticals, Inc. - Conference Presentation Calls
ANX Competitors
| Company | Last | Change | |
| No competitor information is available for ANX. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | ANX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 39.8x |
|
| Price/Book | 7.7x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 40.7x |
Not meaningful
|
|
ANX |
||
ANX transactions
| Type Date |
Target |
|
Private Placement
October 6, 2009 |
-- |
|
Private Placement
August 5, 2009 |
-- |
|
Private Placement
June 29, 2009 |
-- |